Notes from the Eigth International Kidney Cancer Symposium

Conclusions on OptimalSystemic Control For High Risk Patients:  - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently. - There is no evidence that anti-angiogenic agents are anti-metastatic  - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs As a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians…an example is that some patients had incomplete wound healing and had to have their treatment approach altered“on the run”.”************************************************************************************************************************************************************************************ Emerging Applications of VEGF and mTOR-Targeted TherapyCase Presentation and BackgroundBrian I. Rini, M.D.When kidney cancer spreads in the body, it is called metastatic disease. Metastatic disease is the focus of presentations in this session. Dr. Rini presented a stage IV kidney cancer case and discussed initial treatment and follow-up options…subsequent presentations in this session of the symposium were designed to test/influence how the doctor might treat a similar patient in the future.  Standards of...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news